Ultragenyx Pharmaceutical Inc. Preliminary 2025 total revenue of $672 million to $674 million, exceeding top end of guidance Preliminary cash and...
Updates
PAPZIMEOS (zopapogene imadenovec-drba) received full approval by the FDA in August PAPZIMEOS launched with a broad label in the US...
Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025...
Altimmune, Inc 48-week Data from Phase 2b IMPACT Trial of Pemvidutide in MASH Expected Before Year End End-of-Phase 2 Meeting...
Fourth Quarter Update The Company also provided an update on several topics related to its fiscal 2025 fourth quarter, which...
Check out the latest Northwest Austin business updates, including new restaurants, retail options, coffee shops and a gym.Now openAK DentalThe...
